Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15331186 | 0.83 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL6538870 | 0.83 | RAB9A (0.63) | ALDH1A1SMN1; SMN2KDM4EP2RY14MAPT | |
| SCHEMBL24486290 | 0.82 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2KDM4EMAPTLMNA | |
| SCHEMBL29954389 | 0.82 | MAPT (0.64) | ALDH1A1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL6539276 | 0.82 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2KDM4EPKMMAPT | |
| SCHEMBL9112146 | 0.82 | MAPT (0.49) | ALDH1A1SMN1; SMN2PKMRECQLMEN1 | |
| SCHEMBL9112152 | 0.82 | MAPT (0.49) | ALDH1A1SMN1; SMN2PKMRECQLMEN1 | |
| SCHEMBL2559135 | 0.81 | ALDH1A1 (0.63) | ALDH1A1SMN1; SMN2KDM4EKMT2AP2RY14 | |
| SCHEMBL2555132 | 0.81 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2KDM4ERECQL | |
| SCHEMBL15329632 | 0.81 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112574176-B | Heteroaryl compound and application thereof | 隆泰申医药科技(南京) 有限公司 | 2024-03-15 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| CN-107567445-B | 2-phenyl-3H-imidazo [4,5-B ] pyridine derivatives useful as inhibitors of mammalian tyrosine kinase ROR1 activity | 坎塞拉有限公司 | 2021-06-29 | — | — | CN | disclosed |
| WO-2021057696-A1 | HETEROARYL COMPOUND AND APPLICATION THEREOF | 隆泰申医药科技(南京)有限公司 | 2021-04-01 | — | — | WO | disclosed |
| WO-2021057696-A1 | HETEROARYL COMPOUND AND APPLICATION THEREOF | 隆泰申医药科技(南京)有限公司 | 2021-04-01 | — | — | WO | disclosed |
| EP-3253754-B1 | 2-PHENYL-3H-IMIDAZO[4,5-B]PYRIDINE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN TYROSINE KINASE ROR1 ACTIVITY | KANCERA AB (SE) | 2021-03-31 | — | — | EP | disclosed |
| CN-112574176-A | Heteroaryl compound and application thereof | 隆泰申医药科技(南京) 有限公司 | 2021-03-30 | — | — | CN | disclosed |
| US-10550113-B2 | 2-phenyl-3H-imidazo[4,5-B]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity | KANCERA AB (SE) | 2020-02-04 | — | — | US | disclosed |
| US-10501413-B2 | Inhibitors of the Notch transcriptional activation complex and methods for use of the same | UNIVERSITY OF MIAMI (US) | 2019-12-10 | — | — | US | disclosed |
| US-7566716-B2 | Imidazopyrazines as Raf inhibitor compounds | ARRAY BIOPHARMA INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566716-B2 | Imidazopyrazines as Raf inhibitor compounds | ARRAY BIOPHARMA INC. (US) | 2009-07-28 | — | — | US | disclosed |
| EP-1902056-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2008-03-26 | — | — | EP | disclosed |
| US-20060281751-A1 | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA, INC. | 2006-12-14 | — | — | US | disclosed |
| WO-2006125101-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2006-11-23 | — | — | WO | disclosed |
| US-6812235-B2 | 2-ACYLAMINO- BETA -ALANINE DERIVATIVES AND A PHARMACEUTICALLY ACCEPTABLE SALT, USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-02 | — | — | US | disclosed |
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ASTELLAS PHARMA INC. (JP) | 2003-01-23 | — | — | US | disclosed |
| US-5478851-A | Hyperglycemic agent and antilipemic agent | BEECHAM GROUP PLC (GB) | 1995-12-26 | — | — | US | disclosed |
| EP-0555264-A1 | NOVEL COMPOUNDS | BEECHAM GROUP plc (GB) | 1993-08-18 | — | — | EP | disclosed |
| WO-1992007850-A1 | NOVEL COMPOUNDS | BEECHAM GROUP PLC (GB) | 1992-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10501413-B2 | Inhibitors of the Notch transcriptional activation complex and methods for use of the same | NOTCH1, CBFB, HES1 | ALDH1A1 2177/4885SMN1; SMN2 4111/4885KDM4E 422/4885 |
| US-20060281751-A1 | Raf inhibitor compounds and methods of use thereof | BRAF, RAF1, ARAF | ALDH1A1 1780/4885SMN1; SMN2 1831/4885KDM4E 3917/4885 |
| US-10550113-B2 | 2-phenyl-3H-imidazo[4,5-B]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity | ROR1, RORB, RORA | ALDH1A1 317/4885SMN1; SMN2 2170/4885KDM4E 2026/4885 |
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ARRB1, ADRB1, GLRB | ALDH1A1 578/4885SMN1; SMN2 2439/4885KDM4E 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.